SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon jumps on reporting consolidated net profit of Rs 146.7 crore in Q2

21 Oct 2016 Evaluate

Biocon is currently trading at Rs 1019.40, up by 39.15 points or 3.99% from its previous closing of Rs 980.25 on the BSE.

The scrip opened at Rs. 981.30 and has touched a high and low of Rs. 1020.00 and Rs. 978.00 respectively. So far 174055 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1020.00 on 21-Oct-2016 and a 52 week low of Rs. 430.80 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 1020.00 and Rs. 936.85 respectively. The current market cap of the company is Rs. 20248.00 crore.

The promoters holding in the company stood at 60.68%, while Institutions and Non-Institutions held 21.02% and 18.30% respectively.

Biocon has reported 5.53% fall in its net profit at Rs 70.00 crore for the quarter ended September 30, 2016 as compared to Rs 74.10 crore for the same quarter in the previous year. However, the company’s total income has increased by 9.39% to Rs 651.40 crore for the quarter under review from Rs 595.50 crore for the corresponding quarter of the previous year. 

On the consolidated basis, the company has reported a net profit of Rs 146.70 crore for the quarter ended September 30, 2015 as compared to net loss of Rs 10.60 crore for the same quarter in the previous year. Total income of the company has increased by 21.20% at Rs 992.50 crore for quarter under review as compared to Rs 818.90 crore for the quarter ended September 30, 2015.

Biocon Share Price

359.55 -2.75 (-0.76%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×